Alin Abreu-Lomba, David Aristizábal-Colorado, Santiago Sierra-Castillo, Danilo Weir-Restrepo, Carlos Alberto Gómez-Mercado, David Alexander Vernaza Trujillo, Henry Mauricio Arenas-Quintero, Alejandro Castellanos-Pinedo, Clara I Saldarriaga-Giraldo, Alejandro Pinzón-Tovar
{"title":"Prevalence and Characteristics of Heart Disease in Patients with Acromegaly in Colombia (RAPACO HEART Study).","authors":"Alin Abreu-Lomba, David Aristizábal-Colorado, Santiago Sierra-Castillo, Danilo Weir-Restrepo, Carlos Alberto Gómez-Mercado, David Alexander Vernaza Trujillo, Henry Mauricio Arenas-Quintero, Alejandro Castellanos-Pinedo, Clara I Saldarriaga-Giraldo, Alejandro Pinzón-Tovar","doi":"10.1159/000545875","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Acromegaly is a chronic disorder characterized by excessive secretion of growth hormone (GH) and insulin-like growth factor type 1 (IGF-1), resulting in multisystem involvement. Cardiovascular complications affect up to 80% of cases and represent a major concern in advanced stages of the disease. This study aims to determine the prevalence of acromegalic heart disease (AHD) and identify factors associated with its development in a Colombian population.</p><p><strong>Objective: </strong>To evaluate the characteristics of AHD in patients with acromegaly in Colombia.</p><p><strong>Methods: </strong>A retrospective, multicenter case-control study was carried out using data from the national RAPACO registry. Patients aged 16 years or older with confirmed acromegaly and an available echocardiogram were included. AHD was defined by structural or functional cardiac abnormalities attributable to acromegaly.</p><p><strong>Results: </strong>A total of 193 patients with acromegaly were analyzed; 61 (31.6%) had AHD. Compared with the non-AHD group, these patients were older, had a 4.5 cm larger abdominal perimeter, and a median time from disease onset to diagnosis of 8 years (versus 6 years in those without AHD). Among the 61 AHD cases, the most frequent finding was isolated left ventricular hypertrophy (n=32, 52.4%), followed by biventricular hypertrophy (n=12, 19.7%), valvulopathy (n=4, 6.6%), and combined LVH with valvulopathy (n=4, 6.6%). GH and IGF-1 levels were modestly higher in AHD patients. In multivariate analysis, arterial hypertension showed an odds ratio (OR) of 1.75 (95% CI 0.67-4.65) for AHD, while carpal tunnel syndrome significantly increased the odds of AHD (OR 3.81, p=0.01, 95% CI 1.36-11.14).</p><p><strong>Conclusions: </strong>Despite therapeutic advances, AHD remains common in Colombian patients with acromegaly. Notably, carpal tunnel syndrome was independently associated with AHD, alongside hypertension, arrhythmias, and diabetes. These findings underscore the need for proactive cardiovascular screening and management strategies in this patient population.</p>","PeriodicalId":9391,"journal":{"name":"Cardiology","volume":" ","pages":"1-17"},"PeriodicalIF":1.9000,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000545875","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Acromegaly is a chronic disorder characterized by excessive secretion of growth hormone (GH) and insulin-like growth factor type 1 (IGF-1), resulting in multisystem involvement. Cardiovascular complications affect up to 80% of cases and represent a major concern in advanced stages of the disease. This study aims to determine the prevalence of acromegalic heart disease (AHD) and identify factors associated with its development in a Colombian population.
Objective: To evaluate the characteristics of AHD in patients with acromegaly in Colombia.
Methods: A retrospective, multicenter case-control study was carried out using data from the national RAPACO registry. Patients aged 16 years or older with confirmed acromegaly and an available echocardiogram were included. AHD was defined by structural or functional cardiac abnormalities attributable to acromegaly.
Results: A total of 193 patients with acromegaly were analyzed; 61 (31.6%) had AHD. Compared with the non-AHD group, these patients were older, had a 4.5 cm larger abdominal perimeter, and a median time from disease onset to diagnosis of 8 years (versus 6 years in those without AHD). Among the 61 AHD cases, the most frequent finding was isolated left ventricular hypertrophy (n=32, 52.4%), followed by biventricular hypertrophy (n=12, 19.7%), valvulopathy (n=4, 6.6%), and combined LVH with valvulopathy (n=4, 6.6%). GH and IGF-1 levels were modestly higher in AHD patients. In multivariate analysis, arterial hypertension showed an odds ratio (OR) of 1.75 (95% CI 0.67-4.65) for AHD, while carpal tunnel syndrome significantly increased the odds of AHD (OR 3.81, p=0.01, 95% CI 1.36-11.14).
Conclusions: Despite therapeutic advances, AHD remains common in Colombian patients with acromegaly. Notably, carpal tunnel syndrome was independently associated with AHD, alongside hypertension, arrhythmias, and diabetes. These findings underscore the need for proactive cardiovascular screening and management strategies in this patient population.
期刊介绍:
''Cardiology'' features first reports on original clinical, preclinical and fundamental research as well as ''Novel Insights from Clinical Experience'' and topical comprehensive reviews in selected areas of cardiovascular disease. ''Editorial Comments'' provide a critical but positive evaluation of a recent article. Papers not only describe but offer critical appraisals of new developments in non-invasive and invasive diagnostic methods and in pharmacologic, nutritional and mechanical/surgical therapies. Readers are thus kept informed of current strategies in the prevention, recognition and treatment of heart disease. Special sections in a variety of subspecialty areas reinforce the journal''s value as a complete record of recent progress for all cardiologists, internists, cardiac surgeons, clinical physiologists, pharmacologists and professionals in other areas of medicine interested in current activity in cardiovascular diseases.